Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
- 1 March 2010
- journal article
- Published by Taylor & Francis Ltd in mAbs
- Vol. 2 (2), 181-189
- https://doi.org/10.4161/mabs.2.2.11158
Abstract
Engineering the antibody Fc region to enhance the cytotoxic activity of therapeutic antibodies is currently an active area of investigation. The contribution of complement to the mechanism of action of some antibodies that target cancers and pathogens makes a compelling case for its optimization. Here we describe the generation of a series of Fc variants with enhanced ability to recruit complement. Variants enhanced the cytotoxic potency of an anti-CD20 antibody up to 23-fold against tumor cells in CDC assays, and demonstrated a correlated increase in C1q binding affinity. Complement-enhancing substitutions combined additively, and in one case synergistically, with substitutions previously engineered for improved binding to Fc gamma receptors. The engineered combinations provided a range of effector function activities, including simultaneously enhanced CDC, ADCC, and phagocytosis. Variants were also effective at boosting the effector function of antibodies targeting the antigens CD40 and CD19, in the former case enhancing CDC over 600-fold, and in the latter case imparting complement-mediated activity onto an IgG1 antibody that was otherwise incapable of it. This work expands the toolkit of modifications for generating monoclonal antibodies with improved therapeutic potential, and enables the exploration of optimized synergy between Fc gamma receptors and complement pathways for the destruction of tumors and infectious pathogens.Keywords
This publication has 66 references indexed in Scilit:
- Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo modelBlood, 2009
- Structural Difference in the Complement Activation Site of Human IgG1 and IgG3Scandinavian Journal of Immunology, 2009
- Engineered anti‐CD20 antibodies with enhanced complement‐activating capacity mediate potent anti‐lymphoma activityCancer Science, 2009
- Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximabLeukemia Research, 2008
- NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complementBlood, 2008
- Mechanisms of killing by anti-CD20 monoclonal antibodiesMolecular Immunology, 2007
- Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximabBlood, 2006
- Characterization of the Opsonic and Protective Activity against Staphylococcus aureus of Fully Human Monoclonal Antibodies Specific for the Bacterial Surface Polysaccharide Poly- N -AcetylglucosamineInfection and Immunity, 2006
- Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activationMolecular Immunology, 2000
- Amino acid differences in the n-terminus of CH2 influence the relative abilities of IgG2 AND IgG3 to activate complementMolecular Immunology, 1997